N/A N=243 The Mobile Lifestyle Intervention for Food and Exercise Study
Overweight and Obesity · Type2 Diabetes
Primary: Change in Body Weight — -5.3; -3.49 Kg — p=0.09
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=36 Substance Use and Loneliness
Substance Use Disorders
Primary: Mean Change in Loneliness From Baseline to 1-month Post-treatment Follow-up — -1.38; -5.40 score on a scale
Phase 2 N=128 REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With Suvorexant
Delirium in Old Age
Primary: Total Sleep Time (TST) on the First Postoperative Night — 3.91; 3.84 hours — p=0.853
N/A N=57 Improving Adherence to Homework During Therapy
Anxiety · Depression · Depression/Anxiety
Primary: Generalized Anxiety Disorder-7 (Gad-7) — 14.86; 12.88; 8.33; 7.62 units on a scale
N/A N=36 The Effect of Additional Neurodynamic Intervention in Patients With Chronic Ankle Instability
Ankle Sprains
Primary: Pressure Pain Threshold- Anterior Talofibular Ligament — 4.19; 3.98 kg/ cm²
N/A N=809 Randomized Controlled Trial of Game Changers
HIV Prevention
Primary: HIV Testing — 71.60; 71.61 percentage of alters — p=0.95
Phase 2 N=150 Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Primary: Number of Participants With a Major Molecular Response at 12 Months — 103 Participants
Phase 2 N=14 FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
Prostate Cancer
Primary: Median Duration of Response — NA; NA months
Phase 3 N=641 An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)
Asthma
Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 147; 301; 21; 38 Participants
Phase 2 N=169 A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease
Parkinson Disease · Tremor
Primary: Change From Baseline to Week 17 on the Essential Tremor Rating Scale (TETRAS) Composite Outcome Score — -6.4; -5.3 score on a scale — p==0.2363
Phase 1 N=122 A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years
Hepatitis B
Primary: Number of Participants With Solicited Administration Site Adverse Events (AEs) After Dose 1 — 0; 0; 0; 0 Participants
N/A N=30 Parent Acceptance and Commitment Therapy (PACT) for Parents of Children With Pediatric Feeding Disorder
Pediatric Feeding Disorder, Chronic · Pediatric Feeding Dysfunction, Acute
Primary: Patient Health Questionnaire-9 (PHQ-9) — 2; 0; 12; 0 Participants
Phase 3 N=106 A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
Diabetes Mellitus, Type 2 · Chronic Kidney Disease
Primary: Change in Kidney Oxygenation (Cortex), Blood Oxygenation-level Dependent Magnetic Resonance Imaging (BOLD MRI) (R2*) — 0.98; 1.00; 0.98; 0.99 Ratio of kidney oxygenation…
N/A N=138 KanSurvive: Testing a Model for Improving Cancer Survivorship Care in Rural Practice
Breast Cancer · Colorectal Cancer · Lung Cancer
Primary: Tumor Surveillance Completion (Pre-Intervention) — 126 Participants — p=<0.05
Phase 4 N=63 Systems Biological Assessment of Statin Effect on Vaccine Responses
Vaccine Response
Primary: Magnitude of the Antibody (Ab) Response to QIV in Statin Recipients and Non-recipients. — 1.33; 1.46; 1.35; 1.28 log fold-change (logFC)